Presentation is loading. Please wait.

Presentation is loading. Please wait.

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

Published byVincent Andrews Modified over 5 years ago

Similar presentations

Presentation on theme: "Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients."— Presentation transcript:

1 Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. The boxes and lines indicate the RRs and their CIs. Weights are from random-effects analysis. The size of the box indicates the relative weight of each estimate. Diamonds indicate the combined RRs (CKD, chronic kidney disease; IV, intravenous; PO, oral; RRs, relative risks). Shiv Kumar Agarwal et al. Open Heart 2015;2:e000317 ©2015 by British Cardiovascular Society

Download ppt "Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients."

Similar presentations

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.
Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.
Mortality rates in incident ESRD patients figure 9

Mortality rates in incident ESRD patients figure 9
SAVE: Risk of total mortality associated with reduced kidney function

SAVE: Risk of total mortality associated with reduced kidney function
American Journal of Kidney Diseases 

American Journal of Kidney Diseases 
Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.
Ashish Shukla et al. JACEP 2015;1:41-51

Ashish Shukla et al. JACEP 2015;1:41-51
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
John P. Middleton, Patrick H. Pun  Kidney International 

John P. Middleton, Patrick H. Pun  Kidney International 
Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.
Fung TT, et al. Circulation 2009;119:

Fung TT, et al. Circulation 2009;119:
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Volume 81, Issue 7, Pages (April 2012)

Volume 81, Issue 7, Pages (April 2012)
AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.
Chapter 2: Use of iron to treat anemia in CKD

Chapter 2: Use of iron to treat anemia in CKD
Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Volume 68, Issue 5, Pages (November 2005)

Volume 68, Issue 5, Pages (November 2005)

Similar presentations

Ads by Google